Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q1 EPS of ($0.97), $0.82 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $675 thousand.

For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.